The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | Is venetoclax highly efficacious in a subset of MM patients?
Shaji Kumar, MD, from the Mayo Clinic, Rochester, MN, USA, discusses the efficacy of inhibiting Bcl-2 signalling activity, namely through the novel drug, venetoclax, in the treatment of multiple myeloma (MM) patients carrying the t(11;14) translocation. Here, he explains that this subgroup of patients are particularly sensitive to Bcl-2 inhibition due to their cells carrying high levels of Bcl-2 and low levels of Mcl-1 and thus venetoclax is especially efficacious in treating this subgroup of patients, as evidenced in results from clinical trials (NCT01794520). This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
